"Junk DNA" has long been the label pinned on pseudogenes—gene copies inactivated by mutation. A review published in The Innovation Life argues that this "junk" has been quietly shaping how vertebrates conquer new environments—and how humans fall ill.
The human genome alone carries roughly 14,000 pseudogenes, and their distribution is anything but random. Identification strategies now compare across species, screening homologous genes for loss-of-function mutations to separate genuine gene-loss events from assembly errors. What has emerged is a recurring pattern: when a lineage enters a new habitat, genes that once mattered become dispensable—and their inactivation can be adaptive.
The review assembles cases across four phenotypes. In immunity, whales and other marine mammals face bacterial communities unlike those on land; the pattern-recognition receptor TLR5, which detects bacterial flagellin, was pseudogenized in cetaceans, and functional work shows its loss dampens damaging inflammation and improves survival after infection. In sensory adaptation, the naked mole-rat's underground life relaxed selection on vision: multiple phototransduction and retinal-integrity genes accumulated inactivating mutations, producing a highly degenerate eye—a pattern repeated in other subterranean mammals. In metabolism, hummingbirds rely on nectar to power hovering flight; pseudogenization of the muscle-specific gluconeogenic enzyme gene FBP2 enhances glycolytic flux, mitochondrial biogenesis, and respiratory capacity, sharpening carbohydrate use for extreme energy demands. In diet, the giant panda's shift from omnivore to near-exclusive bamboo eater coincided with loss of DUOX2, weakening thyroid-hormone synthesis and lowering basal metabolic rate—an economy suited to low-energy food—while loss of the umami receptor T1R1 may have accompanied the same dietary turn.
Pseudogenes also act in human disease, mostly through duplicated copies that remain transcribed. PTENP1, a pseudogene of the tumor suppressor PTEN, sponges microRNAs and lifts repression on PTEN, curbing cancer-cell proliferation; HBBP1 modulates TAL1 and eases beta-thalassemia; other pseudogene transcripts, such as TDGF1P3, drive tumor progression. Some pseudogenes encode truncated peptides or function as cis-regulatory DNA. In disease networks, the same class of elements can be protective or pathogenic.
The authors flag an asymmetry: pseudogene-derived regulatory RNAs are well documented in human disease but untested in adaptive evolution—largely because adaptation research has centered on unitary pseudogenes, and non-model species resist functional experiments. Long-read RNA sequencing and CRISPR/Cas9 base editing, which can introduce or revert stop codons directly, offer a way to test causal roles. Convergent pseudogenization in distant species facing similar pressures, they add, makes a useful model for the predictability of evolutionary trajectories.
The message: pseudogenes are not passive relics but active participants in gene-expression networks. Losing a gene, in the right lineage at the right time, can be a strategy.
